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Objective: Evidence regarding adjuvant radiation therapy
(ART) and salvage radiation therapy (SRT) following
radical prostatectomy (RP) for prostate cancer is in-
consistent. The study objectives were to collect survey
information on Italian radiation oncologists’ (RO) beliefs
regarding the use of ART and SRT following RP and to
compare the results of Italian RO with those of American
RO available from an analogous survey.
Methods: Amodified version of a US-based questionnaire
captured attitudes and clinical approaches regarding
post-RP RT of all 716 RO practicing in 147 radiation
oncology centres in Italy. Bivariate analyses compared
the responses of Italian RO with those of American RO
retrieved from a previously published study.
Results: Analysable questionnaires were completed by
153 Italian RO (response rate, 21%). Variations in practice
were found for RT use, timing, dosage and technique. All
Italian RO supported ART use, although factors influenc-
ing the decision to initiate ART varied. Most RO (81%)
would wait 3–6 months after surgery before beginning
RT. Compared with Italian RO, more American RO
believed ART improves survival outcomes (70% vs 35%,
p,0.001), would initiate ART based solely on adverse
pathological features (79% vs 69%, p,0.001) and would
initiate SRT based on any detectable prostate-specific
antigen (37% vs 11%, p,0.001).
Conclusion: Italian RO strongly supported ART, but their
approach to patient selection for ART and SRT varied.
Striking differences between Italian RO and American RO
regarding ART and SRT practices were found.
Advance in knowledge: Differential RT practices and
perceptions exist among RO internationally. Clinical
studies must inform evidence-based guidelines to har-
monize the use of post-RP RT.
INTRODUCTION
Radical prostatectomy (RP) is a common evidence-based
strategy for the treatment of localized prostate cancer.
However, in patients with adverse pathological features
(APF) such as seminal vesicle invasion (SVI), extracapsular
extension (ECE) and positive surgical margin (PSM), RP is
associated with a high recurrence rate ranging from 40% to
70%.1 Adjuvant radiation therapy (ART) is administered
soon after RP in the absence of sustained prostate-speciﬁc
antigen (PSA) detection or a rise in PSA following an initial
post-surgical reduction. Three randomized controlled trials
have evaluated the effectiveness of ART, the Arbeitsge-
meinschaft Radiologische Onkologie und Urologische
Onkologie of the German Cancer Society (ARO/AUO) trial
in Germany,2 the European Organization for Research and
Treatment of Cancer (EORTC) trial3 and the Southwest
Oncology Group (SWOG) trial in the USA.4 All three trials
documented increases in biochemical relapse-free survival
compared with observation alone among patients with one
or more APF;2–4 only SWOG demonstrated improvement in
metastases-free survival and overall survival.5 Genitourinary
(GU) and gastrointestinal (GI) adverse effects were more
common in patients receiving radiation therapy (RT), but
few grade 3 or 4 toxicities occurred in either group.2–4
Despite this evidence for ART, many clinicians instead rely
on salvage radiation therapy (SRT), where RT is only ini-
tiated upon a rising PSA following RP. This may be due to
multiple factors including feared toxicity, risk of overtreatment,
as well as an assumed equivalent clinical beneﬁt of ART and
SRT.6 Less than 20% of patients in the USA have been estimated
to receive ART, and utilization did not increase signiﬁcantly after
the results of the prospective trials were published.7,8
We conducted a national web-based survey of Italian radiation
oncologists (RO) to assess the practice of RT following RP in
Italy. Additionally, we sought to compare the survey results of
Italian RO with those of American RO available from an anal-
ogous survey study9 in order to understand international simi-
larities and differences in RT practices. We hypothesized that the
lack of deﬁnitive evidence on how and when to use post-
operative radiation therapy (PORT; ARTor SRT) would result in
signiﬁcant variability in responses among RO within Italy, as
well as signiﬁcant international differences in practice.
METHODS AND MATERIALS
Participants and survey distribution
All 716 Italian RO practicing in the 147 radiation oncology
centres that were listed in the Italian Association of Radiation
Oncology (AIRO) roster (accessed January 2012) were sent
an e-mail invitation from AIRO in February 2012. The survey
invitation contained a brief introductory message and a link
to the web-based instrument. To encourage participation,
AIRO co-ordinated two follow-up e-mails to all participants
within 1 month of the initial e-mailing. No honorarium was
offered; participation was voluntary and anonymous. The
link to the survey was closed 6 weeks after the initial e-mail
invitation.
Survey instrument
The investigators designed the survey instrument using a US-
based questionnaire as a framework. The questionnaire was pre-
viously used in an analogous published survey study and was
provided for use in this study.9 The ﬁnal survey consisted of
a total 33 questions requiring approximately 10min to complete.
Besides demographics, survey domains included the following:
beliefs regarding effectiveness of ART, selection criteria for ART,
timing of ART, PSA threshold for SRT, estimated impact of RTon
toxicity rates, details of surgical technique, RT technique and
dosing and use of hormone therapy (HT) (Supplemental Material
A). The survey was provided in English using an online survey
service (surveymonkey.com) and also on the AIRO website.
Statistical analyses
Italian RO who had treated ﬁve or more patients with prostate
cancer in the previous year and who also responded to questions
regarding perceived effectiveness of ART were included for
analysis. Descriptive statistics were generated for all variables of
interest. To compare responses on beliefs surrounding the use of
ART and SRT as well as perceived toxicity of RT between Italian
RO and American RO, the research team utilized the original
American survey data. Differences between Italian RO and
American RO responses were evaluated using the x2 and Fisher
exact test as appropriate. Data were analysed using SAS statistical
software v. 9.2 (SAS Institute Inc., Cary, NC). The study pro-
tocol was reviewed and deemed exempt by Thomas Jefferson
University’s Institutional Review Board.
RESULTS
A total of 158 participants responded (overall response rate,
22%). Of them, four were excluded because of incomplete data
on ART attitudes and one was excluded because he/she reported
to have treated less than ﬁve patients with prostate cancer in the
previous year. This resulted in an analysable sample of 153
questionnaires (response rate, 21%). Practice and clinician de-
mographic characteristics are presented in Table 1.
Adjuvant radiation therapy beliefs and practices
All Italian RO reported routinely recommending ART following RP,
but under different circumstances (Table 2). 69% of respondents
recommended ART based on APF in the RP specimen alone,
whereas 29% reported using ARTonly in the presence of both APF
and other features such as high Gleason score (GS) and post-
operative PSA value. About one-third (35%) of respondents be-
lieved that ART improves overall survival rates, but the majority
(65%) believed that ART does not provide a survival beneﬁt. When
RO were asked which factor by itself would form the basis for
recommendation of ART (multiple selections were permitted), 92%
of them reported PSM, 66% reported SVI, 66% reported ECE, 7%
reported GS 8–10 and 2% reported detectable PSA after surgery.
When asked about the timing of ART, the majority of RO (81%)
recommended initiating ART 3–6 months following surgery in
order to allow time for post-operative urinary recovery (Table 2).
Salvage radiation therapy practices
The beliefs of RO regarding initiation of SRT following a rise in PSA
varied signiﬁcantly (Table 2), with the most common threshold for
beginning SRTreported as either a PSA of 0.2–0.3ngml21 (43%) or
0.4–0.5ngml21 (23%).
Radiation details
The most commonly reported radiation planning technique was
three-dimensional conformal RT (3DCRT) involving .4 ﬁelds
(58%), followed by intensity-modulated RT (IMRT; 46%) (Table 3).
Larger radiation doses were reported more frequently for SRT
(72%$ 70Gy) and ARTwith surgical margin involvement (72%$
70Gy) than for ART for ECE or SVI (41%$ 70Gy). Weekly portal
ﬁlms were reported as the most frequently utilized image guidance
strategy (60%) (Table 4). The clinical target volume to planning
target volume margin lacked consensus; 34% of RO reported using
a variable margin. Of RO who indicated use of a variable margin,
53% selected a posterior margin of 4–5mm.
Perceptions of toxicity
The perception of PORT-related toxicity was inconsistent across
functional areas, as 20%, 35% and 49% of RO conveyed beliefs
of a moderate to major negative effect on urinary continence
recovery, sexual function recovery and bladder neck contracture
incidence, respectively (Table 2). When asked the extent to
which patients receiving ARTexperience late toxicity, 51% of RO
reported #10% of patients, 26% reported between 11% and
20% of patients and 23% reported .20% of patients. If late
toxicity occurs, RO designated the rectum, bladder and urethra
as primary sites (64%, 23% and 13%, respectively).
Hormone therapy
If ART is initiated, the majority (54%) of RO reported advising
their patients to start HT concurrently if residual disease
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(microscopic or macroscopic), stage disease (ECE or SVI) and a
high GS (.7) are all present (Table 5). Most RO (70%) who
recommend HT reported advising patients to continue HT for
a period of 2 years. Responses of Italian RO regarding PSA and
testosterone monitoring during HT differed substantially (Table 6).
Comparison of Italian and American
radiation oncologists
A greater percentage of American RO practiced in academia
compared with Italian RO (Table 1). Italian and American
respondents were similarly distributed in terms of practice ex-
perience, but signiﬁcantly, more American RO than Italian RO
reported participating in co-operative group trials (53% and
12%, respectively).
A signiﬁcantly greater proportion of American respondents than
Italian respondents believed that ART improves overall survival
outcomes (70% vs 35%, p, 0.001) (Table 2). Differences be-
tween Italian RO and American RO existed in the parameters for
recommending ART after RP. Most Italian and American RO
recommended ART based on APF alone (69% vs 78%), but
more Italian RO than American RO recommended ART only if
both APF and other factors (high GS or post-operative PSA
value) were present (29% vs 13%, p, 0.001). The majority of
Table 1. Demographic characteristics of Italian and American radiation oncologists (RO)
Characteristic Italian RO (N5 153),a n (%) American RO (N5 218),a,b n (%) p-valuec
RO characteristics
Gender
Male 80 (52) –
Female 73 (48) –
Years in practiced
#10 70 (46) 90 (41)
0.5011–20 41 (27) 71 (33)
$21 40 (26) 57 (26)
Number of patients with prostate cancer treated in previous year
5–10 5 (3) –
11–20 17 (11) –
.20 131 (86) –
Participation in co-operative group trialsd
Yes 18 (12) 116 (53)
,0.01
No 134 (88) 102 (47)
Frequency of meeting with pathologist to review prostatectomy specimen
Always (.90% of cases) 9 (6) –
Most of the time (60–90% of cases) 6 (4) –
About half of the time (40–59% of cases) 7 (5) –
Occasionally (10–39% of cases) 55 (36) –
Rarely (,10% of cases) 76 (50) –
Practice characteristics
Academic practice setting
Yes 28 (18) 69 (32)
,0.01
No 125 (82) 149 (68)
Practice location (region of Italy)d
North 78 (54) –
Central 34 (23) –
South 34 (23) –
aPercent sum may not be 100% owing to rounding.
bAmerican RO data are not presented for certain characteristics owing to survey differences.
cp-values using the two-sided x2 test.
dDenominators vary based on available responses.
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Italian and American RO reported waiting between 3 and
6 months following RP to initiate ART (81% vs 70%), but
a larger percentage of American RO were willing to wait more
than 6 months than were Italian RO (26% vs 4%, p, 0.001).
The largest proportion of both Italian and American RO would
initiate SRT in the range of 0.2–0.3 ngml21 (43% vs 50%), but
American RO were signiﬁcantly more likely than Italian RO to
initiate SRT at any detectable PSA (37% vs 11%, p, 0.001).
Table 2. Responses by Italian and US radiation oncologists (RO) regarding recommendations for post-operative radiation therapy
(PORT) and perceptions of radiation toxicity
Response Italian RO (N5 153),a n (%) American RO (N5 218),a n (%) p-valueb
ART
Effect of ART on patient outcomesc
ART improves overall survival rates 54 (35) 150 (70)
,0.01ART improves biochemical control but
not survival
99 (65) 63 (30)
Factors to initiate ARTc
Based on APF alone 105 (69) 166 (78)
,0.01
Based on APF and GS/PSA 44 (29) 28 (13)
If PSA is detectable 4 (3) 15 (7)
Would never use ART 0 (0) 4 (2)
Longest interval to ART initiationc (months)
,3 23 (15) 8 (4)
,0.013–6 120 (78) 149 (70)
.6 6 (4) 56 (26)
SRT
PSA threshold to initiate SRTc (ngml21)
Any detectable 17 (11) 78 (37)
,0.01
0.2–0.3 65 (42) 106 (50)
0.4–0.5 35 (23) 19 (9)
0.6–0.8 14 (9) 7 (3)
$0.9 17 (11) 2 (1)
Would never recommend SRT 3 (2) 0 (0)
PORT
Perceptions of toxicityc
PORT has no/minor effect on urinary
continence recovery for .50% of patients
90 (80) 116 (71)
0.11
PORT has major/total effect on urinary
continence recovery for .50% of patients
23 (20) 47 (29)
PORT has no/minor effect on sexual
function recovery for .50% of patients
69 (65) 96 (59)
0.36
PORT has major/total effect on sexual
function recovery for .50% of patients
38 (35) 67 (41)
PORT has no/mild effect on incidence
of BNC
70 (51) 126 (72)
,0.01
PORT has moderate/severe effect on
incidence of BNC
66 (49) 48 (28)
APF, adverse pathological features; ART, adjuvant radiation therapy; BNC, bladder neck contracture; GS, Gleason score; PSA, prostate-specific
antigen; SRT, salvage radiation therapy.
aPercent sum may not be 100% due to rounding.
bp-values using the two-sided x2 test or Fisher exact test for cell value ,5.
cDenominators vary based on available responses.
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There was no statistically signiﬁcant difference between Italian
RO and American RO opinions on PORT’s effect on urinary
continence or erectile dysfunction recovery. However, a greater
proportion of American RO than Italian RO believe that PORT
has no or minor impact on the incidence of bladder neck
contracture (72% vs 51%, p, 0.001).
In light of signiﬁcant differences between countries in the pro-
portion of respondents afﬁliated with academic institutions
and reporting participation in co-operative group trials, we
performed post hoc stratiﬁed analyses to evaluate whether practice
patterns differed based upon these two characteristics. No signiﬁcant
differences were found with regard to the survey items addressing
survival outcomes with ART, the PSA threshold to initiate SRT or
factors to initiate ART.
DISCUSSION
This work adds to the existing literature9–11 describing RO
beliefs and practices regarding ART and SRT after prostatectomy.
In accordance with RO preferences documented previously,9–11
Italian RO in the present study strongly supported the use of
ART after RP, but their attitude towards timing, duration and
dosage varied substantially. The absence of uniform guidelines12–14
delineating the appropriate PORT strategy for discrete and well-
deﬁned patient populations likely contributes to a practice envi-
ronment characterized by individual interpretation of the
literature.2–4 Differences in resources including equipment, re-
imbursement and stafﬁng, as well as cultural and clinical con-
siderations may also affect the treatment determination following
RP. Our results reﬂect this conﬂuence of factors that exist both
within Italy and internationally.
Only 35% of Italian RO in our study indicated a belief of im-
proved survival outcomes with ART, suggesting that the SWOG
trial provided insufﬁcient evidence to uniformly convince Italian
RO of improved overall survival rates.4,5 Emphasizing potential
differences in the interpretation and acceptance of international
literature,2–4 70% of American RO reported beliefs in improved
survival outcomes with ART. The responses to this survey item
may have been inﬂuenced more strongly by the evidence gen-
erated within each country or region. Multiple Italian institu-
tions participated as trial sites in EORTC trial, which did not
report a long-term survival beneﬁt with ART.3,15 The SWOG
trial, conducted in the USA, did report a survival beneﬁt.5
Italian and American RO both generally recommend ART based
upon APF alone (69% and 78%, respectively). Despite this
principal ﬁnding, a greater proportion of Italian RO than
American RO (29% vs 13%, p, 0.001) would recommend ART
only in the presence of both APF and either an elevated GS or
post-operative PSA value. Although preliminary data exist in
support of PSA and GS as risk factors for disease relapse,2,5,16
insufﬁcient evidence has been published to support the use of
GS or PSA as a predictor of beneﬁt from ART. Surgical margin
status is the leading prognostic factor for predicting biochemical
relapse-free survival and local relapse, independent of other risk
factors.15 The prognostic signiﬁcance of pathological details such
as the extent or number of PSM remains uncertain and requires
further investigation.17 In the absence of requisite data, the
practice of requiring additional risk factors for ART recom-
mendation is of concern. Our survey results also indicated that
only 15% of Italian RO meet frequently with a pathologist to
review prostatectomy specimens. Considering the prognostic
signiﬁcance of PSM, we believe that a multidisciplinary ap-
proach for deﬁning surgical margin status is warranted.
The interval following RP prior to ART initiation was most fre-
quently reported as 3–6 months by Italian (81%) and American
RO (70%). Worrisomely, more than a quarter (26%) of American
RO reported waiting more than 6 months. The prospective
clinical trials administered ART within 3–4 months of RP.2–4
Table 3. Responses by Italian radiation oncologists (RO)
regarding radiation technique and dosing
Response Italian RO (N5 153),a n (%)
Radiation planning techniqueb
3D conformal #4 ﬁelds 50 (33)
3D conformal .4 ﬁelds 88 (58)
IMRT 71 (46)
Arc therapy 27 (18)
Tomotherapy 9 (6)
ART
Radiation dose (standard fractionation) for R0c,d(Gy)
,64 7 (5)
64–66.6 58 (38)
68–68.4 16 (11)
$70 63 (41)
Hypofractionation 8 (5)
Radiation dose (standard fractionation) for R1d,e (Gy)
64–66.6 23 (15)
68–68.4 11 (7)
$70 110 (72)
Hypofractionation 8 (5)
SRT
Radiation dose (standard fractionation)d (Gy)
,64 2 (1)
64–66.6 29 (19)
68–68.4 5 (3)
$70 109 (72)
Hypofractionation 7 (5)
3D, three dimension; ART, adjuvant radiation therapy; IMRT, intensity-modulated
RT; SRT, salvage radiation therapy.
aPercent sum may not be 100% owing to rounding.
bRespondents were allowed to select $1 radiation planning techniques;
percentage sum exceeds 100%.
cRadiation dose used for extracapsular extension or seminal vesicle
invasion.
dDenominators vary based on available responses.
eRadiation dose used for positive surgical margin.
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There are no data supporting the use of ART after more than
6 months except when allowing for recovery from acute side
effects of surgery.6 Otherwise, ART is not indicated at this ex-
tended interval, and monitoring for biochemical failure to initiate
SRT is more clinically appropriate.10,12
The dosing of PORT is expected to vary depending upon the
indication for treatment, ART or SRT, but dose selection must
also incorporate the functional status and toxicity tolerance of
the patient.12 The optimal ART dose for ensuring local control
remains uncertain.18 The dose utilized in the three randomized
trials ranged from 60 to 64Gy, yet 25% of enrolled patients
developed a biochemical recurrence within 5 years at these
dosages.2–4 This may represent a need for use of a dose-escalation
approach; retrospective studies employing a total dose of at least
70Gy have demonstrated a signiﬁcant advantage in terms of
disease-free survival.18,19 A minimum ART dose of 64–65Gy has
been recommended by the American Urological Association and
American Society for Radiation Oncology Guideline Panel, who
have also acknowledged the evidence for safety and improved
tumour control with doses .65Gy.12 Recognizing the need for
dosage individualization based on patient status, 72% of Italian
RO reported using a dose of at least 70Gy in the presence of PSM.
An equal proportion of Italian RO (72%) reported using at least
70Gy for SRT, in line with evidence supporting improved out-
comes at higher doses.20
Regarding the radiation planning technique, Italian RO reported
to use 3DCRT with .4 ﬁelds (58%), followed by IMRT (46%)
and 3DCRT with ,4 ﬁelds (33%). Inconsistent availability of
IMRT among RO practices and insufﬁcient evidence of clinical
superiority likely contribute to the more prevalent use of 3DCRT
in Italy, which was also identiﬁed in a previous survey of Italian
RO.11 Although potential advantages including reduction of GI
toxicities have been associated with IMRT,21,22 the published
literature12 does not reﬂect the implementation of newer radi-
ation techniques in the adjuvant setting, and insufﬁcient evi-
dence exists to conﬁrm a deﬁnitive advantage with IMRT over
3DCRT for toxicity and clinical outcomes.
Despite the fact that the survey responses between Italian RO and
American RO are not technically comparable because of differ-
ential structure of the survey question (Italian survey item: single
response; American survey item: multiple response), it is of note
that 87% of American RO surveyed by Showalter et al9 reported
use of IMRT relative to only 9% 3DCRT. American RO over-
whelming use of IMRT is in stark contrast to the prevailing use of
3DCRT by RO in Italy. One explanatory hypothesis for this dis-
similarity relates to reimbursement incentives present for Amer-
ican RO practices, which are considerably less inﬂuential on
Italian RO practicing in a public healthcare system. Alternatively,
potential beneﬁts of IMRT including reduction of GI toxicities
may be perceived differently between RO in each country.
A primary criticism of ART is the potential for unnecessary
exposure of patients whose prostate cancer may never have re-
curred to RT-related toxicities, yet the tolerability of ART
remains unclear. In the SWOG trial, both urethral stricture and
urinary incontinence were more common among patients who
received ART.4 By contrast, an interim analysis of the EORTC
trial did not show an increased risk of urinary incontinence with
ART.23 No difference in the incident of urethral stricture was
found in the ARO/AUO trial, which is the only study that used
3DCRT.2 Moreover, data from observational studies using
3DCRT have not shown signiﬁcant grade 3 late GI or GU
toxicities.12,19 Perceptions of PORT toxicities were similar be-
tween American RO and Italian RO regarding urinary conti-
nence and sexual function recovery. A statistically and likely
clinically signiﬁcant difference in perceived effect of PORT on
bladder neck contracture incidence was observed; 49% of Italian
RO reported beliefs of a moderate/severe effect compared with
Table 4. Responses by Italian radiation oncologists (RO)
regarding imaging methods and margin definition
Response
Italian RO
(N5 153),a n (%)
Image guidance method for RPb
Weekly port ﬁlms 90 (60)
Daily port ﬁlms without ﬁducial markers
or clips
13 (9)
Daily port ﬁlms with ﬁducial markers
or clips
3 (2)
Cone beam CT 44 (29)
CT-on-rails 1 (1)
Ultrasound –
Use of endorectal balloonb
No 145 (97)
Sometimes 5 (3)
CTV to PTV marginb
,3mm 0 (0)
3mm 4 (3)
4–5mm 23 (15)
6–7mm 20 (13)
8–9mm 18 (12)
1.0 cm 31 (20)
1.1–1.5 cm 4 (3)
Variable 52 (34)
If variable CTV to PTV, what posterior margin?b
,3mm 2 (2)
3mm 15 (11)
4–5mm 70 (53)
6–7mm 31 (23)
8–9mm 14 (11)
1.0 cm 1 (1)
CTV, clinical target volume; PTV, planning target volume; RP, radical
prostatectomy.
aPercent sum may not be 100% due to rounding.
bDenominators vary based on available responses.
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28% of American RO. Additional anticipated toxicity may inﬂuence
the decision of Italian RO to reserve ART for patients with multiple
risk factors for relapse.
Several factors likely inﬂuence the attitudes of RO towards ART
and SRT, with both approaches possibly justiﬁed. Apart from
patients with SVI, recurrences after RP are usually local.24
Therefore, early local treatment may prevent locoregional diffu-
sion. Additionally, since ART is administered for undetectable
disease, it may be effective at lower doses than SRT.25 The chief
beneﬁt of SRT is the avoidance of overtreatment of patients who
are not destined to recur. Substantial variability exists with regards
to the timing of SRT initiation, with the largest proportion of
Italian RO having identiﬁed 0.2–0.3 ngml21 as the PSA threshold
for beginning SRT. Greater inconsistency was apparent in-
ternationally, as 37% of American RO would recommend SRT at
any detectable PSA compared with only 11% of Italian RO. Im-
proved outcomes following SRT have been attained when RTwas
initiated earlier, notably at any detectable PSA and in the presence
of a slower PSA doubling time.16,24 Observational studies16,26 have
suggested that SRTreduces PSA recurrence, distant metastases and
prostate cancer–speciﬁc death, but the use of SRT is not presently
supported by evidence from randomized controlled trials.
The role of concurrent ARTand HTafter RP is unclear. Our study
found HT to be recommended under varying circumstances by
89% of surveyed RO, with most practitioners (54%) advising HT
for patients at high risk due to residual disease (microscopic or
macroscopic), ECE or SVI and a high GS (.7). Similar results of
a 2011 survey of Canadian RO indicated that approximately half
of the RO (55%) would recommend HT to high-risk patients.10
The 2-year duration of HT selected most frequently in our study
(70%) was aligned with limited evidence supporting concurrent
ART and HT.19 Interim results of a randomized controlled trial
investigating concurrent SRT and 2 years of HT post RP dem-
onstrated longer freedom from biochemical progression and
a reduction in metastases; longer follow-up is required to de-
termine the signiﬁcance of an overall survival beneﬁt.27
In summary, the results of our survey of Italian RO taken
contextually with previous surveys of American9 and Canadian10
RO underscore the large magnitude international variation in
post-RP use of RT. Our results support the hypothesis that
a large amount of variability in the use of PORT is derived from
RO practice, which is based upon insufﬁcient evidence in the
published literature2–4 and a corresponding lack of deﬁnitive
practice guidelines.12–14 Nonetheless, additional variation due to
the structure of healthcare systems, as well as individual or so-
cietal preferences, likely exists. Academic and professional edu-
cational curricula, cultural values, reimbursement incentives and
the availability of new technology each have the potential to
contribute to distinct local and national practice environments.
Furthermore, patient reported preferences are expected to im-
pact treatment decisions. Future investigations are necessary to
prospectively evaluate real-world use of ART and SRT for
comparison with subjectively reported RO preferences while also
characterizing the inﬂuence of societal and patient factors on
PORT utilization.
This study has limitations. A primary limitation of survey
methodology was the focus upon physician preferences, which
were subject to reporting bias and may inaccurately represent
actual RT utilization. Furthermore, our survey only captured the
preferences and practice patterns of RO. Evaluating the practice
patterns of urologists would be important to understand the
management of the overall patient population with prostate
cancer and the characteristics of patients referred by urologists
for RO treatment. It is also important to acknowledge the period
of time (approximately 1.5 years) separating the administration
of the American and Italian surveys, during which time the
dissemination of evidence may have contributed to differences
in practice patterns observed between countries. Furthermore,
time has passed since the survey was administered and practice
patterns may have evolved.
A potential limitation stems from the absence of information
regarding RO speciality within the AIRO list, since ideally we
would survey only RO with a stated speciality in GU cancers. To
overcome this limitation, we restricted our analytic sample to
Italian RO who had treated at least ﬁve patients with prostate
cancer in the previous year. Furthermore, the majority (86%) of
RO (Table 1) reported treating .20 patients in that timeframe,
indicative of extensive experience among sampled RO. The
AIRO list contained 147 Italian radiation oncology centres, and
we anticipate that one to two RO with experience treating
Table 5. Responses by Italian radiation oncologists (RO)
regarding hormone therapy (HT)
Response
Italian RO
(N5 153),a n (%)
Advise patients beginning ART Post RP to start HTb
Yes, always 13 (9)
Yes, only when there is residual diseasec 17 (12)
Yes, only when there is residual diseasec
and stage diseased
22 (15)
Yes, only when there is residual diseasec,
stage diseased and a high GS (.7)
80 (54)
Never 16 (11)
Suggested duration if HT is givenb (years)
#1 31 (22)
2 98 (70)
3 4 (3)
Depends on risk factors 8 (6)
Percentage of patients discontinuing HT early owing to adverse effects
#10 129 (84)
11–20 16 (10)
.20 8 (5)
ART, adjuvant radiation therapy; GS, Gleason score; RP, radical
prostatectomy.
aPercent sum may not be 100% owing to rounding.
bDenominators vary based on available responses.
cResidual disease includes microscopic and macroscopic disease.
dStage disease includes extracapsular invasion or vesicle invasion.
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prostate cancer were practicing at each centre. Considering the
153 responses we received in the context of 147 Italian radiation
oncology centres, we are conﬁdent that the responses of sampled
RO are representative of the beliefs and ongoing practices of RO
treating prostate cancer in Italy.
The survey of American RO was conducted separately prior to our
research, but while it was not identical, the American survey tool
was highly conserved and provided the framework for our survey.
To prevent the introduction of bias, comparisons using data from
the American RO study were only made on survey items that
remained entirely consistent across both studies (Tables 1 and 2).
CONCLUSION
This national survey of Italian RO highlights the considerable
agreement among Italian RO regarding ART’s use after RP based
upon APF while also emphasizing differential PORT practices and
perceptions both within Italy and internationally. Further research
should focus on informing the joint clinician–patient decision re-
garding RT after RP by deﬁning high-risk patient populations for
which ART is appropriate. Ongoing studies [(e.g. Radiotherapy-
Adjuvant Versus Early Salvage (RAVES), Radiotherapy and Androgen
Deprivation in Combination After Local Surgery (RADICALS)]
comparing ART with SRT post RP are necessary to better deﬁne
such populations and characterize the toxicity burden associated
with newer treatment modalities (i.e. IMRT), ensuring that the
quality of life is appropriately considered alongside clinical and
survival outcomes in future treatment algorithms.
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